Shanghai Henlius Biotech and Organon (OGN) announced that the FDA has approved the biologics license application for Poherdy 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to Perjeta, for all indications of the reference product. Poherdy is the first and only approved pertuzumab biosimilar in the U.S.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN: